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Tyrosine kinase inhibitors (TKI) are widely used to treat patients with leukemia driven by BCR-
ABL11 and other oncogenic tyrosine kinases2,3. Recent efforts focused on the development of 
more potent TKI that also inhibit mutant tyrosine kinases4,5. However, even effective TKI 
typically fail to eradicate leukemia-initiating cells6–8, which often cause recurrence of leukemia 
after initially successful treatment. Here we report on the discovery of a novel mechanism of drug-
resistance, which is based on protective feedback signaling of leukemia cells in response to TKI-
treatment. We identified BCL6 as a central component of this drug-resistance pathway and 
demonstrate that targeted inhibition of BCL6 leads to eradication of drug-resistant and leukemia-
initiating subclones.
BCL6 is a known proto-oncogene that is often translocated in diffuse large B cell lymphoma 
(DLBCL)9. In response to TKI-treatment, BCR-ABL1 acute lymphoblastic leukemia (ALL) cells 
upregulate BCL6 protein levels by ~90-fold, i.e. to similar levels as in DLBCL (Fig. 1a). 
Upregulation of BCL6 in response to TKI-treatment represents a novel defense mechanism, which 
enables leukemia cells to survive TKI-treatment: Previous work suggested that TKI-mediated cell 
death is largely p53-independent. Here we demonstrate that BCL6 upregulation upon TKI-
treatment leads to transcriptional inactivation of the p53 pathway. BCL6-deficient leukemia cells 
fail to inactivate p53 and are particularly sensitive to TKI-treatment. BCL6−/− leukemia cells are 
poised to undergo cellular senescence and fail to initiate leukemia in serial transplant recipients. A 
combination of TKI-treatment and a novel BCL6 peptide inhibitor markedly increased survival of 
NOD/SCID mice xenografted with patient-derived BCR-ABL1 ALL cells. We propose that dual 
targeting of oncogenic tyrosine kinases and BCL6-dependent feedback (Supplementary Fig. 1) 
represents a novel strategy to eradicate drug-resistant and leukemia-initiating subclones in tyrosine 
kinase-driven leukemia.
To elucidate mechanisms of TKI-resistance in tyrosine kinase-driven leukemia, we 
performed a gene expression analysis including our and published data of TKI-treated 
leukemia. We identified BCL6 as a top-ranking gene in a set of recurrent gene expression 
changes10, some of which are shared with MEK inhibition in BRAFV600E mutant solid 
tumor cells11 (Supplementary Fig. 2–3). TKI-induced upregulation of BCL6 mRNA levels 
was confirmed in multiple leukemia subtypes carrying oncogenic tyrosine kinases 
(Supplementary Fig. 2). The BCR-ABL1 kinase, encoded by the Philadelphia chromosome 
(Ph), represents the most frequent genetic lesion in adult ALL, defines the subtype with a 
particularly poor prognosis1,4,5 and was therefore chosen as focus for this study.
To elucidate the regulation of BCL6 in Ph+ ALL, we investigated the JAK2/STAT512 and 
PI3K/AKT13 pathways downstream of BCR-ABL1. We and others have shown that STAT5 
suppresses BCL6 in B cells14–16. TKI-mediated upregulation of BCL6 was diminished by 
constitutively active STAT5(Fig. 1b) and deletion of STAT5 was sufficient to upregulate 
BCL6, even in the absence of TKI-treatment (Fig. 1c). In agreement with previous work16, 
overexpression of FoxO4 induced BCL6 (Fig. 1d). In Ph+ ALL cells, FoxO factors are 
inactivated by PI3K/AKT13 signaling, which is reversed by Pten (Supplementary Fig. 4). 
Deletion of Pten, hence, abrogated the ability of the leukemia cells to upregulate BCL6 in 
response to TKI-treatment (Fig. 1e).
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In DLBCL, BCL6 is frequently translocated and suppresses p53-mediated apoptosis9,17. 
While TKI-treatment is less effective in p53−/− Ph+ ALL18, recent studies showed that TKI 
paradoxically prevent the upregulation of p53 in response to DNA damage in Ph+ ALL and 
CML19,20. A comparative gene expression analysis of BCL6−/− and BCL6+/+ ALL cells 
(Supplementary Fig. 5) identified Cdkn2a (Arf), Cdkn1a (p21), p53 and p53bp1 as potential 
BCL6 target genes (Supplementary Fig. 6). Arf and p53 protein levels were indeed 
unrestrained in BCL6−/− ALL (Fig. 2a). TKI-treatment of BCL6+/+ ALL resulted in strong 
upregulation of BCL6 with low levels of p53, while BCL6−/−ALL cells failed to curb p53 
expression levels (Supplementary Fig. 7). Likewise, TKI-treatment increased excessively 
p53 levels when Pten-deficient ALL cells failed to upregulate BCL6 (Fig. 1e).
Identifying direct targets of BCL6 by chromatin immunoprecipitation in Ph+ ALL 
(Supplementary Fig. 8–11), p53, p21 and p27 were among the genes with the strongest 
recruitment of BCL6 in TKI-treated ALL (Fig. 2b; Supplementary Fig. 9–11). Given that 
cell cycle-arrest and senescence-associated genes were among the BCL6 targets, we studied 
the cell cycle profile of leukemia cells. BCL6−/− ALL cells divided at a slightly reduced rate 
compared to BCL6+/+ ALL cells (Fig. 2c). Treatment with adriamycin (0.05 μg/ml) had no 
significant effect on BCL6+/+ ALL cells in a senescence-associated β-galactosidase assay21–
22
 but revealed that the vast majority of BCL6−/− leukemia cells was poised to undergo 
cellular senescence (Fig. 2d). These findings demonstrate that even low levels of BCL6 in 
the absence of TKI-treatment are critical to downregulate Arf/p53.
Clonal evolution of leukemia involves acquisition of genetic lesions through DNA 
damage23. Interestingly, a CGH analysis revealed that genetic lesions were less frequent in 
BCL6 deficient ALL (Supplementary Fig. 12), suggesting that increased sensitivity to DNA 
damage limits clonal evolution in the absence of BCL6. Since Arf and p53 are critical 
negative regulators of self-renewal24, we performed colony-forming assays. The colony 
frequencies of BCL6−/− ALL cells were reduced by ~20-fold compared to BCL6+/+ ALL 
(Fig. 3a). To study self-renewal in vivo, we measured the ability of BCL6+/+ and BCL6−/− 
ALL cells to initiate leukemia in transplant recipients (Fig. 3b). Using luciferase bioimaging, 
leukemia engraftment was observed in both groups after 8 days. BCL6+/+ ALL cells rapidly 
expanded and initiated fatal leukemia, whereas BCL6−/− ALL cells failed to expand from 
the initial engraftment foci (Fig. 3c). Some mice that received BCL6−/− ALL cells ultimately 
succumbed to leukemia (Fig. 3b). Flow cytometry, however, revealed that the leukemias in 
the BCL6−/− group were in fact derived from endogenous CD45.1+ cells of the irradiated 
recipients and not from the injected CD45.2+ donor ALL cells (Supplementary Fig. 13; 
asterisks in Fig. 3b).
Defective leukemia-initiation may be a consequence of impaired homing to the bone 
marrow niche. Indeed, BCL6−/− ALL cells lack expression of CD44 (Supplementary Fig. 
14), which is critical for homing of BCR-ABL1 leukemia-initiating cells (LIC) to the bone 
marrow microenvironment25. Retroviral reconstitution of CD44 markedly increased homing 
of BCL6−/− ALL cells to the bone marrow niche, but failed to rescue defective leukemia-
initiation (Supplementary Fig. 14).
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Using intrafemoral injection to circumvent homing defects, a limiting dilution experiment 
(Fig. 3d) showed that 5 million BCL6−/− ALL cells compared to only 103 BCL6+/+ ALL 
cells were needed to initiate fatal leukemia. These findings suggest that the frequency of LIC 
in BCL6−/− ALL (<1 in 100,000) is reduced by >100-fold compared to BCL6+/+ ALL (≥1 in 
1,000). An alternative interpretation would be that LIC occur at a similar frequency in 
BCL6−/− ALL but with reduced self-renewal activity. To address potential “exhaustion” of 
LIC, we performed a serial transplantation with ALL cells that gave rise to disease in 
primary recipients after injection of 5 million ALL cells. From the bone marrow, we isolated 
CD19+ ALL cells for secondary intrafemoral injection. BCL6−/− leukemia was not 
transplantable in secondary recipients (Supplementary Fig. 15). While these findings do not 
rule out the possibility that the LIC frequencies are reduced in BCL6−/− ALL, they support 
the notion of LIC “exhaustion” after secondary transplantation.
To explore the therapeutic usefulness of pharmacological inhibition of BCL6, we tested a 
BCL6 inhibitor (RI-BPI), which blocks the repressor activity of BCL626. Gene expression 
analysis confirmed that RI-BPI is a selective and potent inhibitor of BCL6 (Supplementary 
Fig. 16). We investigated the effect of RI-BPI on the self-renewal capacity of primary Ph+ 
ALL and the initiation of leukemia in a mouse xenograft model. Treatment with RI-BPI 
resulted in a reduction of colony formation and delayed progression of leukemia. Likewise, 
treatment of Ph+ ALL with RI-BPI induced cellular senescence (Supplementary Fig. 17).
We next examined how gene dosage of BCL6 affects responses to TKI. For instance, 
Pten−/− ALL cells lack the ability to upregulate the p53-repressor BCL6 and are more 
sensitive to Imatinib (Fig. 1e; Supplementary Fig. 18). Dose-response studies in BCL6+/+, 
BCL6+/− and BCL6−/− ALL (Fig. 4a) showed that Imatinib-sensitivity was significantly 
increased in BCL6−/− (EC50: 0.17 μmol/l) and even in BCL6+/− ALL cells (EC50: 0.67 
μmol/l) compared to BCL6+/+ ALL cells (EC50: 1.10 μmol/l; Fig. 4a). These findings 
indicate that maximum levels of BCL6 expression are required to prevent TKI-induced cell 
death. Indeed, inducible activation of BCL6-ERT2 constructs27 in BCL6−/− ALL cells 
conferred a strong survival advantage in the presence of Imatinib (Fig. 4b). Activation of 
BCL6 in BCL6+/+ ALL cells induced cell cycle exit (not shown) and no additional survival 
advantage, because these cells already achieved maximal upregulation of endogenous BCL6 
(Fig. 1a).
To address the role of BCL6-mediated repression of p53 in TKI-resistance, p53−/− and 
p53+/+ ALL cells were treated with RI-BPI. The synergistic effect between TKI-treatment 
and RI-BPI is indeed partially p53-dependent (Supplementary Fig. 19). In p53−/− ALL cells, 
the effect of RI-BPI was significantly diminished compared to p53+/+ ALL.
To confirm that BCL6 has a similar function in patient-derived Ph+ ALL, primary ALL cells 
were transduced with a dominant-negative BCL6 mutant (DN-BCL6-ERT2)27, which 
resulted in a marked competitive disadvantage of Ph+ ALL cells, that was further enhanced 
by Imatinib treatment (Fig. 4c). Similar observations in mouse ALL and in an established 
Ph+ ALL cell line demonstrate that BCL6 promotes survival of TKI-treated Ph+ ALL 
(Supplementary Fig. 20).
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To test the effect of BCL6 inhibition on TKI-resistance, we cultured 4 primary Ph+ ALL in 
the presence or absence of Imatinib, RI-BPI or a combination of both (Supplementary Fig. 
21). Initially, all 4 Ph+ ALL cases responded to Imatinib treatment, but subsequently 
rebounded and were no longer sensitive to Imatinib (10 μmol/l). RI-BPI alone showed only 
slight effects, while the combination of RI-BPI and Imatinib rapidly induced cell death and 
effectively prevented a rebound in all 4 cases (Supplementary Fig. 21). These findings 
suggest that prolonged treatment with a combination of Imatinib/RI-BPI prevents 
acquisition of TKI-resistance. We next examined the effect of Imatinib/RI-BPI combinations 
on primary TKI-resistance in Ph+ ALL. To this end, 4 human Ph+ ALL cell lines that lack 
BCR-ABL1 kinase mutations (Supplementary Table 1) but are highly refractory to Imatinib 
(10 μmol/l) were treated with or without Imatinib, RI-BPI or a combination of both. Imatinib 
alone did not achieve a therapeutic response, whereas the combination with RI-BPI 
potentiated the effect of Imatinib on the refractory ALL cells (Supplementary Fig. 22).
To study the efficacy of combined tyrosine kinase and BCL6 inhibition in vivo, primary Ph+ 
ALL cells were labeled with luciferase and xenografted into mice. Recipient mice were 
treated with either vehicle, Nilotinib or a combination of Nilotinib and RI-BPI. Nilotinib is 
more potent than Imatinib, which only has marginal effects in mice28,29. Bioimaging 
demonstrated that 7–10 injections of RI-BPI significantly enhanced the effect of Nilotinib 
(Fig. 4d–e and Supplementary Fig. 23). While all mice treated with Nilotinib alone 
succumbed to leukemia within 99 days after injection, 7 of 8 mice treated with RI-BPI/
Nilotinib combination were still alive after 140 days (Fig. 4d–e). Also in a model for full-
blown mouse leukemia, TKI/RI-BPI combinations proved effective and significantly 
prolonged survival (Supplementary Fig. 24). Establishing a potential therapeutic window of 
Nilotinib/RI-BPI combinations, we found no evidence of relevant toxicity (Supplementary 
Fig. 25–26; Supplementary Table 2).
Although transcription factors have been considered intractable therapeutic targets, the 
recent development of a small molecule inhibitor against BCL630 holds promise to 
effectively target TKI-resistance in patients with Ph+ ALL. Since TKI-resistance develops in 
virtually all cases of Ph+ ALL, it appears particularly important to target this novel pathway 
of TKI-resistance.
Methods summary
Cell culture
Primary leukemia cells (Supplementary Table 1) were cultured on OP9 stroma cells in 
Alpha MEM without ribonucleotides and deoxyribonucleotides, supplemented with 20% 
FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 IU/ml penicillin, and 100 μg/ml 
streptomycin. Human ALL cell lines were maintained in RPMI with GlutaMAX containing 
20% FBS, 100 IU/ml penicillin, and 100 μg/ml streptomycin. Mouse BCR-ABL1-
transformed ALL cells were maintained in IMDM with GlutaMAX containing 20% FBS, 
100 IU/ml penicillin, 100 μg/ml streptomycin, and 50 μM 2-mercaptoethanol. Cell cultures 
were kept at 37°C in a humidified incubator under a 5% CO2 atmosphere.
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BCR-ABL1 transformation
Transfection of a MSCV-based retroviral vector encoding BCR-ABL1 was performed using 
Lipofectamine 2000. Retroviral supernatant was produced by co-transfecting 293FT cells 
with the plasmids pHIT60 and pHIT123. Virus supernatant were harvested, filtered through 
a 0.45 μm filter and loaded by centrifugation (2,000 × g, 90 min at 32°C) on 50μg/ml 
RetroNectin coated non-tissue well plates. Extracted bone marrow cells from mice were 
transduced by BCR-ABL1 in the presence of 10 ng/ml recombinant murine Interleukin-7 
(IL-7) in RetroNectin-coated petri dishes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Regulation of BCL6 expression in BCR-ABL1 ALL cells
a, Ph+ ALL cells were treated with and without Imatinib (10 μmol/l) for 24 hours. 
Upregulation of BCL6 was compared to expression levels in DLBCL with BCL6-IGH 
translocation by Western blot. b, BCR-ABL1-transformed mouse ALL cells were transduced 
with a constitutively active Stat5 mutant (STAT5-CA) or a control vector (GFP) and treated 
either with or without Imatinib. BCL6 Western blot was performed using β-actin as loading 
control. c, BCL6 expression upon Imatinib-treatment was studied by Western blot in the 
presence or absence of Cre-mediated deletion of Stat5 in BCR-ABL1-transformed Stat5fl/fl 
mouse ALL. d, Mouse BCR-ABL1 ALL cells were transduced with FoxO4-Puromycin or a 
Puromycin control vector and subjected to antibiotic selection. Cells were harvested and 
BCL6 mRNA levels were measured by qRT-PCR relative to Hprt. e, Imatinib-induced 
BCL6 expression was studied by Western blot in the presence or absence of Cre-mediated 
deletion of Pten in BCR-ABL1-transformed Ptenfl/fl mouse ALL cells.
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Figure 2. BCL6 is required for transcriptional inactivation of the Arf/p53 pathway in BCR-
ABL1 ALL
a, Western blot analysis of CDKN2A (Arf) and p53 expression in BCL6−/− and BCL6+/+ 
BCR-ABL1 ALL cells. b, Human Ph+ ALL cells (Tom1) were treated with and without 
Imatinib (10 μmol/l) for 24 hours and were subjected to ChIP-on-chip analysis using a 
BCL6-specific antibody. The y-axis indicates enrichment versus input and the x-axis the 
location of probes within the respective loci relative to the transcriptional start site. The dark 
and light green (Control) or red (Imatinib) tracings depict two replicates. Recruitment to 
CDKN1A, CDKN1B, TP53 and HPRT (negative control) is shown in Ph+ ALL cells and one 
DLBCL cell line (OCI-Ly7). c, Cell cycle analysis (BrdU/7-AAD staining). d, Staining for 
senescence-associated β-galactosidase (SA-β-gal). ALL cells were treated with or without 
0.05 μg/ml adriamycin for 48 hours to induce a low level of DNA damage. Percentages of 
SA-β-gal+ cells are indicated (means ± SD; n=3).
Duy et al. Page 10
Nature. Author manuscript; available in PMC 2013 March 14.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. BCL6 is required for leukemia-initiation in BCR-ABL1 ALL
a, 10,000 BCL6−/− or BCL6+/+ BCR-ABL1 ALL cells were plated in semisolid agar, and 
colonies were counted after ten days (numbers denote means ± SD, n=3). b, Overall survival 
of mice injected with 100,000 BCL6−/− and BCL6+/+ BCR-ABL1 ALL cells was compared 
by Kaplan-Meier analysis. c, For a SCID leukemia-initiating cell (SL-IC) experiment, 
BCL6−/− and BCL6+/+ BCR-ABL1 ALL cells were labeled with firefly luciferase and were 
intravenously injected into sublethally irradiated NOD/SCID mice. Mice that developed 
CD45.1+ endogenous leukemia instead of leukemia from injected CD45.2+ cells are 
indicated by asterisks (see Supplementary Fig. 13). d, The SL-IC assay was repeated as a 
limiting dilution experiment (103, 104, 105, 5 million cells) and leukemia cells were directly 
injected into the femoral bone marrow to circumvent potential engraftment defects.
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Figure 4. BCL6 promotes survival of TKI-treated BCR-ABL1 ALL cells
a, Imatinib-sensitivity of BCL6−/−, BCL6+/− and BCL6+/+ ALL cells was measured in a 
Resazurin viability assay. b, BCL6−/− ALL cells were transduced with BCL6-ERT2 or ERT2 
vectors (tagged with GFP). ALL cells were treated with or without 1 μmol/l Imatinib, and 
BCL6-ERT2 or ERT2 were induced by 4-OHT. Relative changes of GFP+ cells after 
induction are indicated. c, Patient-derived Ph+ ALL cells (ICN1) were transduced with 
inducible dominant-negative BCL6 (DN-BCL6-ERT2) or ERT2 control vectors. ALL cells 
were treated with or without 10 μmol/l Imatinib and DN-BCL6-ERT2 or ERT2 were induced 
by 4-OHT. Relative changes of GFP+ cells after induction are indicated. d, Patient-derived 
Ph+ ALL cells (TXL2) were labeled with luciferase and 100,000 cells were injected. Mice 
were treated 7 times with either vehicle (gray), Nilotinib (25 mg/kg; green) or a combination 
of Nilotinib and RI-BPI (25 mg/kg; red). Treated mice are shown in e, a Kaplan-Meier 
survival analysis. Treatment days are indicated by arrow heads.
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